Skip to content
Tagged COVID-19 Biotechnology SARS-CoV-2 Life Science cancer CORONAVIRUS pandemic
BioXone

BioXone

rethinking future

November 18, 2026
  • About
  • BiotechTodayNews
    • IndiaWeekly Biotech News of India
    • WorldWeekly Biotech News of The World
  • DNA-TalesArticles
    • BiotechnopediaInteresting articles written by BioXone members and associates.
    • Scientists’ CornerArticles from the pioneers of Biotechnology.
    • Cellular CommunicationInterview of greatest researchers’ in the field.
  • Myth-LysisFact Check
  • Signalling PathwayCareer related updates
    • ExaminationsExamination related articles.
    • Job and InternshipJobs and Internship related articles.
  • Courses
  • Contact

Most Viewed This Week

July 13, 2026July 13, 2026

Why Do We Age? The Biology Of Ageing Explained

1
October 17, 2023October 16, 2023

The Corrosion Prediction from the Corrosion Product Performance

2
October 1, 2023September 30, 2023

Nitrogen Resilience in Waterlogged Soybean plants

3
September 28, 2023September 28, 2023

Cell Senescence in Type II Diabetes: Therapeutic Potential

4
September 26, 2023September 25, 2023

Transgene-Free Canker-Resistant Citrus sinensis with Cas12/RNP

5
September 25, 2023September 25, 2023

AI Literacy in Early Childhood Education: Challenges and Opportunities

6

Search Field

Subscribe Now

  • Home
  • BiotechToday
  • mRNA-1273 shows promising results after Phase 3 trial

Hydrogel biomaterial significantly improves wound healing

Govt Gene Editing Project Recruitment at NABI | Applications Invited

mRNA-1273 shows promising results after Phase 3 trial
  • BiotechToday
  • World

mRNA-1273 shows promising results after Phase 3 trial

bioxone November 19, 2020November 19, 2020

Prama Ghosh, Amity University Kolkata

An interim review shared by an independent data and safety monitoring board (DSMB) about mRNA-1273 – a COVID-19 vaccine overseeing its Phase 3 trial suggests that the vaccine is safe and effective at preventing symptomatic COVID-19 in adults after its interim analysis with the trial oversight group on Nov. 15, 2020. 

The data from the interim analysis which comprised 95 cases of symptomatic COVID-19 among volunteers reported that the candidates were safe and the efficacy rate of the vaccine was 94.5%. The vaccine was well tolerated by the volunteers. 

The mRNA-1273 vaccine candidate co-developed by Moderna, Inc., a Cambridge, Massachusetts-based biotechnology company and the National Institute of Allergy and Infectious Diseases (NIAID) as a part of the National Institutes of Health combines mRNA (messenger RNA) from Moderna as a delivery platform with the stabilized SARS-CoV-2 spike immunogen (S-2P) developed by NIAID scientists. 

 Results from earlier stage clinical testing which included more than 30,000 participants at 100 clinical research sites in the United States indicated that the vaccine candidate is well-tolerated and immunogenic. 

The Phase 3 vaccine efficacy trial of the vaccine which is known as COVE was sponsored by Moderna and begun under a multi-agency collaboration led by HHS and the Department of Defense known as Operation Warp Speed (OWS). The trial was funded by Biomedical Advanced Research and Development Authority (BARDA) and National Institute of Allergy and Infectious Diseases (NIAID).

Also read: Hydrogel biomaterial significantly improves wound healing

Reference: https://www.nih.gov/news-events/news-releases/promising-interim-results-clinical-trial-nih-moderna-covid-19-vaccine

  • Why Do We Age? The Biology Of Ageing Explained
  • The Corrosion Prediction from the Corrosion Product Performance
  • Nitrogen Resilience in Waterlogged Soybean plants
  • Cell Senescence in Type II Diabetes: Therapeutic Potential
  • Transgene-Free Canker-Resistant Citrus sinensis with Cas12/RNP

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X

Related

Tagged Biomedical Advanced Research and Development Authority COVID-19 Covid-19 vaccine human health human health services mRNA – 1273 National Institute of Allergy and Infectious Diseases phase 3 trial SARS-CoV-2 spike immunogen

One thought on “mRNA-1273 shows promising results after Phase 3 trial”

  1. Pingback: Heme-antibody reaction can now prove to be a boon in therapeutics - BioXone

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Next Post
  • Job and Internship
  • Signaling Pathway

Govt Gene Editing Project Recruitment at NABI | Applications Invited

bioxone November 20, 2020

-Shristi Sharma, Team bioXone NABI JRF & Project Fellow Recruitment – Applications Invited. Govt NABI Junior Research Fellow Jobs. National Agri-Food Biotechnology Institute (NABI) is hiring for research positions. NABI job opportunity details, project details, application procedure details given below: Download Application Form (Word Doc) National Agri-Food Biotechnology Institute (NABI) (Dept. of Biotechnology, Govt. of […]

Related Post

  • BiotechToday
  • World

Awareness among Saudi Women about Cancer & Carcinogens

BioTech Today May 6, 2022May 5, 2022

Rajyashree Basu, University Of Calcutta (Lady Brabourne College) Saudi Arabia has seen a rise in cancer cases through the decades- between 1999 and 2015 the cases rose by 136%, and are predicted to rise by 63% by the year 2030. The study in this discussion was aimed at exploring the knowledge of the general women […]

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X
  • BiotechToday
  • World

Autism Spectrum Disorder its occurrence in Preterm Infants

bioxone August 13, 2021August 13, 2021

Avani Dave, Jai Hind College Preterm newborns’ survival rates have risen thanks to advances in neonatal intensive care. The danger of long-term neurodevelopmental morbidity in many preterm and extremely preterm babies is well established. Research suggests that even moderate to late-preterm babies are susceptible to such negative consequences. Prematurity and low birth weight have recently […]

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X
  • BiotechToday
  • World

Artificial Intelligence (AI) for efficient COVID Testing

BioTech Today June 23, 2021June 22, 2021

Vaishnavi Kardale, Bioinformatics Centre, Savitribai Phule Pune University For the past one and a half years, we have been struggling with COVID19. The deadly pandemic has taken millions of lives all over the world. Meanwhile, the huge demand has deaccelerated the vaccine rollout. The plan to deal with COVID19 includes extensive testing, contact tracing, quarantining, […]

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X

Breaking News

Why Do We Age? The Biology Of Ageing Explained

The Corrosion Prediction from the Corrosion Product Performance

Nitrogen Resilience in Waterlogged Soybean plants

Cell Senescence in Type II Diabetes: Therapeutic Potential

Transgene-Free Canker-Resistant Citrus sinensis with Cas12/RNP

AI Literacy in Early Childhood Education: Challenges and Opportunities

Sustainable Methanol Vapor Sensor Made with Molecularly Imprinted Polymer

Terms and Conditions
Shipping and Delivery Policy
Cancellation and Refund Policy
Contact Us
Privacy Policy